keyword
MENU ▼
Read by QxMD icon Read
search

Neuro-oncology

keyword
https://www.readbyqxmd.com/read/28325997/a-comprehensive-approach-in-high-grade-glioma-management-position-statement-from-the-neuro-oncology-scientific-club-nosc-shiraz-iran
#1
REVIEW
Mansour Ansari, Ahmad Mosalaei, Niloufar Ahmadloo, Alireza Rasekhi, Bita Geramizadeh, Ali Razmkon, Kazem Anvari, Mohammad Afarid, Ali Dadras, Leila Nafarieh, Mohammad Mohammadianpanah, Hamid Nasrolahi, Seyed Hasan Hamedi, Shapour Omidvari, Mohammad Nami
Establishing a robust teamwork model in the practice of neuro-oncology requires continued interdisciplinary efforts. The Neuro-Oncology Scientific Club (NOSC) initiative is an interdisciplinary clinical forum promoting the comprehensive approach across involved disciplines in the management of central nervous system (CNS) malignancies. With its provincial founding panels and national steering board, NOSC has been operational in Iran since 2011. This initiative has pursued its mission through interval strategic meetings, tumor boards, case discussions as well as publishing neuro-oncology updates, case study periodicals, and newsletters...
2017: German Medical Science: GMS E-journal
https://www.readbyqxmd.com/read/28321824/therapeutic-hypothesis-testing-with-rodent-brain-tumor-models
#2
REVIEW
Derek A Wainwright, Craig M Horbinski, Rintaro Hashizume, C David James
The development and application of rodent models for preclinical testing of novel therapeutics and approaches for treating brain tumors has been a mainstay of neuro-oncology preclinical research for decades, and is likely to remain so into the foreseeable future. These models serve as an important point of entry for analyzing the potential efficacy of experimental therapies that are being considered for clinical trial evaluation. Although rodent brain tumor models have seen substantial change, particularly since the introduction of genetically engineered mouse models, certain principles associated with the use of these models for therapeutic testing are enduring, and form the basis for this review...
March 20, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28315827/contemporary-management-of-low-grade-glioma-a-paradigm-shift-in-neuro-oncology
#3
REVIEW
Caroline Hayhurst
Supratentorial diffuse intrinsic low-grade gliomas represent a distinct but heterogenous group of tumours, with the propensity to grow and to differentiate into malignant tumours. They have been historically viewed in the 'benign' spectrum of intrinsic brain tumours, so a watch-and-wait policy was often adopted. With recent advances in our understanding of the natural history of these tumours, combined with advances in surgical technique, an aggressive approach is now recommended. Increasing quality evidence of the impact of tumour resection and multicentre trials of adjuvant radiotherapy and chemotherapy have led to a new algorithm for low-grade glioma management...
March 18, 2017: Practical Neurology
https://www.readbyqxmd.com/read/28314689/dna-methylation-based-classification-and-grading-system-for-meningioma-a-multicentre-retrospective-analysis
#4
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper, Dominik Sturm, Hans-Georg Wirsching, Anna Sophie Berghoff, Peter Baumgarten, Annekathrin Kratz, Kristin Huang, Annika K Wefers, Volker Hovestadt, Martin Sill, Hayley P Ellis, Kathreena M Kurian, Ali Fuat Okuducu, Christine Jungk, Katharina Drueschler, Matthias Schick, Melanie Bewerunge-Hudler, Christian Mawrin, Marcel Seiz-Rosenhagen, Ralf Ketter, Matthias Simon, Manfred Westphal, Katrin Lamszus, Albert Becker, Arend Koch, Jens Schittenhelm, Elisabeth J Rushing, V Peter Collins, Stefanie Brehmer, Lukas Chavez, Michael Platten, Daniel Hänggi, Andreas Unterberg, Werner Paulus, Wolfgang Wick, Stefan M Pfister, Michel Mittelbronn, Matthias Preusser, Christel Herold-Mende, Michael Weller, Andreas von Deimling
BACKGROUND: The WHO classification of brain tumours describes 15 subtypes of meningioma. Nine of these subtypes are allotted to WHO grade I, and three each to grade II and grade III. Grading is based solely on histology, with an absence of molecular markers. Although the existing classification and grading approach is of prognostic value, it harbours shortcomings such as ill-defined parameters for subtypes and grading criteria prone to arbitrary judgment. In this study, we aimed for a comprehensive characterisation of the entire molecular genetic landscape of meningioma to identify biologically and clinically relevant subgroups...
March 14, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28304010/establishment-of-site-specific-multi-disciplinary-tumour-boards-in-pakistan-sharing-experience-of-neuro-oncology-team-based-at-a-tertiary-care-university-hospital
#5
Muhammad Waqas, Ahmed Nadeem Abbasi
No abstract text is available yet for this article.
March 2017: JPMA. the Journal of the Pakistan Medical Association
https://www.readbyqxmd.com/read/28303929/neuro-oncology-new-therapeutic-targets-for-diffuse-intrinsic-pontine-glioma
#6
Charlotte Ridler
No abstract text is available yet for this article.
March 17, 2017: Nature Reviews. Neurology
https://www.readbyqxmd.com/read/28290395/indian-society-of-neuro-oncology-consensus-guidelines-for-the-contemporary-management-of-medulloblastoma
#7
Tejpal Gupta, Chitra Sarkar, Vedantam Rajshekhar, Sandip Chatterjee, Neelam Shirsat, Dattatreya Muzumdar, Sona Pungavkar, Girish Chinnaswamy, Rakesh Jalali
INTRODUCTION: The high success rate in the management medulloblastoma achieved in the western world is not exactly mirrored in developing countries including India. Socio-demographic differences, health-care disparity, and lack in uniformity of care with resultant widespread variations in the clinical practice are some of the reasons that may partly explain this difference in outcomes. Patients with medulloblastoma require a multi-disciplinary team approach involving but not limited to neuro-radiology, neurosurgery; neuropathology, molecular biology, radiation oncology, pediatric medical oncology and rehabilitative services for optimizing outcomes...
March 2017: Neurology India
https://www.readbyqxmd.com/read/28283219/pet-mri-multiparametric-imaging-of-brain-tumors
#8
Jiří Ferda, Eva Ferdová, Ondřej Hes, Jan Mraček, Boris Kreuzberg, Jan Baxa
A combination of morphological imaging of the brain with microstructural and functional imaging provides a comprehensive overview of the properties of individual tissues. While diffusion weighted imaging provides information about tissue cellularity, spectroscopic imaging allows us to evaluate the integrity of neurons and possible anaerobic glycolysis during tumor hypoxia, in addition to the presence of accelerated synthesis or degradation of cellular membranes; on the other hand, PET metabolic imaging is used to evaluate major metabolic pathways, determining the overall extent of the tumor ((18)F-FET, (18)F-FDOPA, (18)F-FCH) or the degree of differentiation ((18)F-FDG, (18)F-FLT, (18)F-FDOPA and (18)F-FET)...
February 22, 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28277832/amino-acid-pet-in-neuro-oncology-applications-in-the-clinic
#9
Norbert Galldiks, Karl-Josef Langen
No abstract text is available yet for this article.
March 11, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28276498/the-impact-of-the-rbm4-initiated-splicing-cascade-on-modulating-the-carcinogenic-signature-of-colorectal-cancer-cells
#10
Jung-Chun Lin, Yuan-Chii Lee, Yu-Chih Liang, Yang C Fann, Kory R Johnson, Ying-Ju Lin
A growing body of studies has demonstrated that dysregulated splicing profiles constitute pivotal mechanisms for carcinogenesis. In this study, we identified discriminative splicing profiles of colorectal cancer (CRC) cells compared to adjacent normal tissues using deep RNA-sequencing (RNA-seq). The RNA-seq results and cohort studies indicated a relatively high ratio of exon 4-excluded neuro-oncological ventral antigen 1 (Nova1(-4)) and intron 2-retained SRSF6 (SRSF6(+intron 2)) transcripts in CRC tissues and cell lines...
March 9, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28275886/comparing-available-criteria-for-measuring-brain-metastasis-response-to-immunotherapy
#11
Jack M Qian, Amit Mahajan, James B Yu, A John Tsiouris, Sarah B Goldberg, Harriet M Kluger, Veronica L S Chiang
The response assessment in neuro-oncology (RANO) working group recently proposed standardized response criteria for brain metastases (RANO-BM). We sought to compare RANO-BM to other criteria in an ongoing brain metastasis trial. The first 36 patients enrolled on NCT02085070, an ongoing trial of pembrolizumab for patients with untreated brain metastases, were included in this analysis. As RANO-BM had not been proposed when the protocol was written, response on trial was assessed using an institutional modification of RECIST 1...
March 8, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28272232/continuous-dose-intense-temozolomide-and-cisplatin-in-recurrent-glioblastoma-patients
#12
Yu Wang, Xiangyi Kong, Yi Guo, Renzhi Wang, Wenbin Ma
In glioblastoma multiforme (GBM), both temozolomide (TMZ) and cisplatin are very active at various toxic levels. Previous studies demonstrated that cisplatin with the standard regimen of TMZ is active in patients suffering from recurrent GBM, generating a moderate level of toxicity. Also, continuous dose-intense TMZ is a helpful therapy for patients with recurrent GBM. We have conducted a research to evaluate the security and effectiveness of cisplatin with constant dose-intense TMZ for reduplicative GBM. The time to progression (TTP) and progression-free survival (PFS) at 6 months (PFS-6) was the major end point...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28259296/critical-review-of-the-addition-of-tumor-treating-fields-ttfields-to-the-existing-standard-of-care-for-newly-diagnosed-glioblastoma-patients
#13
REVIEW
M Mehta, P Wen, R Nishikawa, D Reardon, K Peters
Since 2005, the standard of care for patients with newly diagnosed glioblastoma (GBM) has consisted of maximal resection followed by radiotherapy plus daily temozolomide (TMZ), followed by maintenance TMZ. In patients selected for clinical trials, median overall survival (OS) and progression-free survival (PFS) with this regimen is 15-17 months and 6-7 months, respectively. There have been various, largely unsuccessful attempts to improve on this standard of care. With the FDA approval of the tumor-treating fields (TTFields) device, Optune, for recurrent GBM (2011), and the more recent EF-14 interim trial results and approval for newly diagnosed GBM patients, several questions have arisen...
March 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28258444/response-assessment-of-bevacizumab-therapy-in-gbm-with-integrated-11c-met-pet-mri-a-feasibility-study
#14
Cornelius Deuschl, Christoph Moenninghoff, Sophia Goericke, Julian Kirchner, Susanne Köppen, Ina Binse, Thorsten D Poeppel, Harald H Quick, Michael Forsting, Lale Umutlu, Ken Herrmann, Joerg Hense, Marc Schlamann
BACKGROUND: The objective of this study was to evaluate the potential of integrated 11C-MET PET/MR for response assessment of relapsed glioblastoma (GBM) receiving bevacizumab treatment. METHODS: Eleven consecutive patients with relapsed GBM were enrolled for an integrated 11C-MET PET/MRI at baseline and at follow-up. Treatment response for MRI was evaluated according to Response Assessment in Neuro-oncology (RANO) criteria and integrated 11C-MET PET was assessed by the T/N ratio...
March 3, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28257280/applying-the-international-classification-of-functioning-children-and-youth-version-to-pediatric-neuro-oncology
#15
Thomas Pletschko, Anna Felnhofer, Agathe Schwarzinger, Liesa Weiler, Irene Slavc, Ulrike Leiss
Given the increased survival rates in patients with pediatric central nervous system tumors, late effects such as treatment- and/or illness-related neurologic sequelae as well as neuropsychological deficits and social difficulties have moved into focus in follow-up care. In order to provide personalized treatment recommendations for pediatric brain tumor survivors, it is crucial not only to assess cognitive impairments but also to measure a patient's functional deficiencies, for example, restricted participation in everyday social activities...
January 2017: Journal of Child Neurology
https://www.readbyqxmd.com/read/28254872/pet-mri-for-oncological-brain-imaging-a-comparison-of-standard-mr-based-attenuation-corrections-with-a-novel-model-based-approach-for-the-siemens-mmr-pet-mr-system
#16
Ivo Rausch, Lucas Rischka, Claes N Ladefoged, Julia Furtner, Matthias Fenchel, Andreas Hahn, Rupert Lanzenberger, Marius E Mayerhoefer, Tatjana Traub-Weidinger, Thomas Beyer
To compare attenuation correction (AC) approaches for positron emission tomography/magnetic resonance imaging (PET/MRI) in clinical neuro-oncology. Methods: Forty-nine PET/MRI brain scans were included: brain tumor studies using (18)F-FET (n = 31) and 68-Ga-DOTANOC (n = 7) and studies of healthy subjects using (18)F-FDG (n = 11). For each subject, MR-based AC maps (MR-AC) were acquired using the standard DIXON- (DIXON) and UTE-based (UTE) approaches. A third MR-AC was calculated using a model-based, post-processing approach to account for bone attenuation values (BD, non-commercial prototype software by Siemens Healthcare)...
March 2, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28210785/on-glioblastoma-and-the-search-for-a-cure-where-do-we-stand
#17
REVIEW
John Bianco, Chiara Bastiancich, Aleksander Jankovski, Anne des Rieux, Véronique Préat, Fabienne Danhier
Although brain tumours have been documented and recorded since the nineteenth century, 2016 marked 90 years since Percival Bailey and Harvey Cushing coined the term "glioblastoma multiforme". Since that time, although extensive developments in diagnosis and treatment have been made, relatively little improvement on prognosis has been achieved. The resilience of GBM thus makes treating this tumour one of the biggest challenges currently faced by neuro-oncology. Aggressive and robust development, coupled with difficulties of complete resection, drug delivery and therapeutic resistance to treatment are some of the main issues that this nemesis presents today...
February 17, 2017: Cellular and Molecular Life Sciences: CMLS
https://www.readbyqxmd.com/read/28208698/advances-in-molecular-imaging-of-locally-delivered-targeted-therapeutics-for-central-nervous-system-tumors
#18
REVIEW
Umberto Tosi, Christopher S Marnell, Raymond Chang, William C Cho, Richard Ting, Uday B Maachani, Mark M Souweidane
Thanks to the recent advances in the development of chemotherapeutics, the morbidity and mortality of many cancers has decreased significantly. However, compared to oncology in general, the field of neuro-oncology has lagged behind. While new molecularly targeted chemotherapeutics have emerged, the impermeability of the blood-brain barrier (BBB) renders systemic delivery of these clinical agents suboptimal. To circumvent the BBB, novel routes of administration are being applied in the clinic, ranging from intra-arterial infusion and direct infusion into the target tissue (convection enhanced delivery (CED)) to the use of focused ultrasound to temporarily disrupt the BBB...
February 8, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28204993/needs-of-neuro-oncological-patients-and-their-caregivers-during-the-hospitalization-and-after-discharge-results-from-a-longitudinal-study
#19
C Scaratti, M Leonardi, A Saladino, E Anghileri, M Broggi, E Lamperti, L Fariselli, R Ayadi, G Tringali, S Schiavolin
PURPOSE: The aims of this study are to identify neuro-oncological patients' and their caregivers' needs during hospitalization (T0) and at 4 months after discharge (T1); to analyze the longitudinal changes in patients' and caregivers' needs and burden; to identify correlations between patients' needs and caregivers' burden and needs. METHODS: A pilot observational longitudinal study was conducted on 94 neuro-oncological patients and their caregivers using NEQ to evaluate patients' needs, CNA, and FSQ for caregivers' needs and burden at T0 and T1...
February 15, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28197403/network-plasticity-and-intraoperative-mapping-for-personalized-multimodal-management-of-diffuse-low-grade-gliomas
#20
REVIEW
Cristina Diana Ghinda, Hugues Duffau
Gliomas are the most frequent primary brain tumors and include a variety of different histological tumor types and malignancy grades. Recent achievements in terms of molecular and imaging fields have created an unprecedented opportunity to perform a comprehensive interdisciplinary assessment of the glioma pathophysiology, with direct implications in terms of the medical and surgical treatment strategies available for patients. The current paradigm shift considers glioma management in a comprehensive perspective that takes into account the intricate connectivity of the cerebral networks...
2017: Frontiers in Surgery
keyword
keyword
1438
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"